Zhejiang Cancer Hospital
🇨🇳China
Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06254066
Ciprofol EC50 for Inducing Loss of Consciousness in Elderly Patients
Phase 4
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT06253078
- Locations
- 🇨🇳
Jiangling Wang, Hangzhou, Zhejiang, China
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 276
- Registration Number
- NCT06214195
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
SBRT Sequential Surufatinib Combined With Immunotherapy for Biliary Tract Carcinoma
Phase 2
Suspended
- Conditions
- Interventions
- First Posted Date
- 2024-01-10
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT06199882
- Locations
- 🇨🇳
Liu luying, Hangzhou, Zhejiang, China
Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT06195683
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-01-08
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 220
- Registration Number
- NCT06195670
- Locations
- 🇨🇳
Ji Zhu, Hangzhou, Zhejiang, China
A Clinical Study of Sintilimab as Adjuvant Therapy in Node-positive ESCC
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT06190639
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Ciprofol Sedation in Patients Undergoing Liver Cancer Percutaneous Radiofrequency Ablation
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06178926
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT06173466
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-11-20
- Last Posted Date
- 2023-11-20
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT06140576
- Locations
- 🇨🇳
ZhejiangCH, Hangzhou, Zhejiang, China
© Copyright 2024. All Rights Reserved by MedPath